Breaking news

American Travelers Thrive Overseas as U.S. Faces Tourism Decline

A Surge in American Travelers Abroad

As American families pack their bags and head overseas, a stark contrast emerges as international tourists to the U.S. dwindle. Caroline Smith, an accounting director from New Jersey, found herself bumping into familiar faces from her hometown during an Easter break trip to Italy. This trend reflects a wider pattern where Americans are increasingly choosing to explore international destinations.

Declining U.S. Inbound Tourism

According to the International Trade Administration, the number of foreign visitors to the U.S. by air saw a nearly 10% drop in March this year. This shift could deepen the existing $50 billion gap between U.S. travel-generated revenue and what Americans spend overseas, raising concerns for the domestic travel industry.

Economic Implications and Industry Voices

Leaders like American Airlines CEO Robert Isom emphasize the need for a streamlined visa process to reinvigorate interest from international tourists. Highlighting the economic ripple effect, JPMorgan projects a potential 0.1% dip in U.S. GDP tied to decreased foreign travel spend.

Social and Media Influences on Travel Choices

Social media and television shows are increasingly influencing travel decisions. Whether inspired by a scene in “The White Lotus” or a hit show set in Paris, American travelers, including students celebrating graduations, seek memorable international experiences.

Future Outlook for U.S. Tourism

While retirees are utilizing their wealth to travel abroad, there is concern over reduced domestic and business travel bookings. However, airlines like Delta and United remain hopeful, with strong international sales through the summer.

For further insights, explore our coverage on Cyprus Tourism Trends.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

Aretilaw firm
eCredo
Uol
The Future Forbes Realty Global Properties

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter